The introduction of targeted genomic sequence changes into living cells and organisms has become a powerful tool for biological research and is a potential avenue for therapy of genetic diseases. Frameshift knockout mutations enable reverse genetics and identification of gene functions; sequence insertions can fuse epitope tags or other functional domains, such as fluorescent proteins, to endogenous gene products; and specific sequence alterations can induce amino acid substitutions for disease modeling, transfer traits in agricultural crops and livestock, and correct defective genes for therapeutic applications. For many years, strategies for efficiently inducing precise, targeted genome alterations were limited to certain organisms (e.g., homologous recombination in yeast or recombineering in mice) and often required drug-selectable markers or left behind 'scar' sequences associated with the modification method (e.g., residual loxP sites from Cre recombinase-mediated excision). Targeted genome editing using customized nucleases provides a general method for inducing targeted deletions, insertions and precise sequence changes in a broad range of organisms and cell types. The high efficiency of genome editing obviates the need for additional sequences, such as drug-resistance marker genes, and therefore the need for additional manipulations to remove them.
r e v i e w
The introduction of targeted genomic sequence changes into living cells and organisms has become a powerful tool for biological research and is a potential avenue for therapy of genetic diseases. Frameshift knockout mutations enable reverse genetics and identification of gene functions; sequence insertions can fuse epitope tags or other functional domains, such as fluorescent proteins, to endogenous gene products; and specific sequence alterations can induce amino acid substitutions for disease modeling, transfer traits in agricultural crops and livestock, and correct defective genes for therapeutic applications. For many years, strategies for efficiently inducing precise, targeted genome alterations were limited to certain organisms (e.g., homologous recombination in yeast or recombineering in mice) and often required drug-selectable markers or left behind 'scar' sequences associated with the modification method (e.g., residual loxP sites from Cre recombinase-mediated excision). Targeted genome editing using customized nucleases provides a general method for inducing targeted deletions, insertions and precise sequence changes in a broad range of organisms and cell types. The high efficiency of genome editing obviates the need for additional sequences, such as drug-resistance marker genes, and therefore the need for additional manipulations to remove them.
A crucial first step for performing targeted genome editing is the creation of a DNA double-stranded break (DSB) at the genomic locus to be modified 1 . Nuclease-induced DSBs can be repaired by one of at least two different pathways that operate in nearly all cell types and organisms: nonhomologous end-joining (NHEJ) and homology-directed repair (HDR) (Fig. 1) . NHEJ can lead to the efficient introduction of insertion/deletion mutations (indels) of various lengths, which can disrupt the translational reading frame of a coding sequence or the binding sites of trans-acting factors in promoters or enhancers. HDR-mediated repair can be used to introduce specific point mutations or to insert desired sequences through recombination of the target locus with exogenously supplied DNA 'donor templates' . With targeted nuclease-induced DSBs, the frequencies of these alterations are typically greater than 1% and, in some cases, over 50%; at these rates, desired mutations can be identified by simple screening, without drug-resistance marker selection.
Early methods for targeting DSB-inducing nucleases to specific genomic sites relied on protein-based systems with customizable DNAbinding specificities, such as meganucleases, zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs). These platforms have made possible important advances, but each has its own set of associated advantages and disadvantages (Box 1). More recently, a platform based on a bacterial CRISPR-associated protein 9 nuclease from Streptococcus pyogenes (hereafter referred to as Cas9) has been developed; it is unique and flexible owing to its dependence on RNA as the moiety that targets the nuclease to a desired DNA sequence. In contrast to ZFN and TALEN methods, which use protein-DNA interactions for targeting, RNA-guided nucleases (RGNs) use simple, base-pairing rules between an engineered RNA and the target DNA site.
In this Review, we describe how this RNA-guided system works and how it has been applied to perform genome editing across a wide variety of cell types and whole organisms. We also discuss the advantages and limitations of this system, and assess off-target effects and recent strategies for improving specificity and how the system can be repurposed for other applications, such as regulation of gene expression and selective labeling of the genome (Fig. 2 summarizes different  applications) . Finally, we consider the challenges that will need to be addressed for this emerging genome editing platform. Targeted genome editing using engineered nucleases has rapidly gone from being a niche technology to a mainstream method used by many biological researchers. This widespread adoption has been largely fueled by the emergence of the clustered, regularly interspaced, short palindromic repeat (CRISPR) technology, an important new approach for generating RNA-guided nucleases, such as Cas9, with customizable specificities. Genome editing mediated by these nucleases has been used to rapidly, easily and efficiently modify endogenous genes in a wide variety of biomedically important cell types and in organisms that have traditionally been challenging to manipulate genetically. Furthermore, a modified version of the CRISPR-Cas9 system has been developed to recruit heterologous domains that can regulate endogenous gene expression or label specific genomic loci in living cells. Although the genome-wide specificities of CRISPR-Cas9 systems remain to be fully defined, the power of these systems to perform targeted, highly efficient alterations of genome sequence and gene expression will undoubtedly transform biological research and spur the development of novel molecular therapeutics for human disease. r e v i e w From a bacterial CRISPR immune system to engineered RGNs CRISPR systems are adaptable immune mechanisms used by many bacteria to protect themselves from foreign nucleic acids, such as viruses or plasmids [2] [3] [4] [5] . Type II CRISPR systems incorporate sequences from invading DNA between CRISPR repeat sequences encoded as arrays within the bacterial host genome (Fig. 3a) . Transcripts from the CRISPR repeat arrays are processed into CRISPR RNAs (crRNAs), each harboring a variable sequence transcribed from the invading DNA, known as the "protospacer" sequence, and part of the CRISPR repeat. Each crRNA hybridizes with a second RNA, known as the transactivating CRISPR RNA (tracrRNA) 6 , and these two RNAs complex with the Cas9 nuclease 7 . The protospacer-encoded portion of the crRNA directs Cas9 to cleave complementary target-DNA sequences, if they are adjacent to short sequences known as protospacer adjacent motifs (PAMs). Protospacer sequences incorporated into the CRISPR locus are not cleaved presumably because they are not next to a PAM sequence.
The type II CRISPR system from S. pyogenes has been adapted for inducing sequence-specific DSBs and targeted genome editing 7 . In the simplest and most widely used form of this system, two components must be introduced into and/or expressed in cells or an organism to perform genome editing: the Cas9 nuclease and a guide RNA (gRNA), consisting of a fusion of a crRNA and a fixed tracrRNA (Fig. 3b) . Twenty nucleotides at the 5′ end of the gRNA (corresponding to the protospacer portion of the crRNA; Fig. 3c ) direct Cas9 to a specific target DNA site using standard RNA-DNA complementarity basepairing rules. These target sites must lie immediately 5′ of a PAM sequence that matches the canonical form 5′-NGG (although recognition at sites with alternate PAM sequences (e.g., 5′-NAG) has also been reported, albeit at less efficient rates [7] [8] [9] ). Thus, with this system, Cas9 nuclease activity can be directed to any DNA sequence of the form N 20 -NGG simply by altering the first 20 nt of the gRNA to correspond to the target DNA sequence. Type II CRISPR systems from other species of bacteria that recognize alternative PAM sequences and that utilize different crRNA and tracrRNA sequences have also been used for targeted genome editing [10] [11] [12] . However, because the most commonly used and extensively characterized system is based on the S. pyogenes system, the remainder of this Review focuses on this particular platform and its components, unless otherwise noted.
Following the initial demonstrations in 2012 that Cas9 could be programmed to cut various DNA sites in vitro 7 , a flurry of papers published in 2013 showed that this platform also functions efficiently in a variety of cells and organisms. Initial proof-of-principle studies showed that Cas9 could be targeted to endogenous genes in bacteria 8 , cultured transformed human cancer cell lines and human pluripotent stem cells in culture [13] [14] [15] [16] , as well as in a whole organism, the zebrafish (J.K.J. and colleagues 17 ). Subsequently, Cas9 has been used to alter 
Box 1 Meganucleases, ZFNs and TALENs
Meganucleases, ZFNs and TALENs have been used extensively for genome editing in a variety of different cell types and organisms. Meganucleases are engineered versions of naturally occurring restriction enzymes that typically have extended DNA recognition sequences (e.g., 14-40 bp). ZFNs and TALENs are artificial fusion proteins composed of an engineered DNA binding domain fused to a nonspecific nuclease domain from the FokI restriction enzyme. Zinc finger and TALE repeat domains with customized specificities can be joined together into arrays that bind to extended DNA sequences. The engineering of meganucleases has been challenging for most academic researchers because the DNA recognition and cleavage functions of these enzymes are intertwined in a single domain 86, 87 . By contrast, the DNA binding domains of ZFNs and TALENs are distinct from the FokI cleavage domain 88 , thereby making it more straightforward to modify the DNA-binding specificities of these nucleases. However, robust construction of engineered zinc finger arrays has also proven to be difficult for many laboratories because of the need to account for context-dependent effects between individual finger domains in an array 89 . Despite the availability of various publicly available methods designed to simplify the challenge of creating ZFNs 90-96, (J.K.J. and colleagues 92, 93, 95 ), these nucleases have not been engineered by a wide range of laboratories.
In contrast to zinc fingers, TALE repeat domains seem to have fewer context-dependent effects and can be assembled robustly in a modular fashion to recognize virtually any DNA sequence (J.K.J. and colleagues 97 ), using a simple one-to-one code between individual repeats and the four possible DNA nucleotides 98, 99 . Although TALE repeat domains are much simpler to design than meganucleases or ZFNs, the assembly of DNA molecules encoding large numbers of highly conserved TALE repeats can require the use of nonstandard molecular biology cloning methods. Many user-friendly methods for making such assemblies have been described in the literature (J.K.J. and colleagues 100 ) but the highly repetitive nature of TALEN-coding sequences also creates barriers to their delivery using certain viral vectors, such as lentiviruses 101 . Nonetheless, the greater simplicity of TALENs relative to meganucleases and ZFNs has led to their adoption over the past several years by a broad range of scientists. The question of whether to utilize these platforms for a given application must be considered on a case-by-case basis, and we refer the reader to recent reviews on these different technologies for additional information 86,88,100 . npg r e v i e w genes in yeast 18 , tobacco 19, 20 , thale cress 19 , rice 21, 22 , wheat 21 , sorghum 23 , mice 24, 25 , rats 26 , rabbits 27 , frogs 28 , fruit flies 29, 30 , silkworms 31 and roundworms 32 (see Table 1 for a list of these published reports). Cas9-induced DSBs have been used to introduce NHEJ-mediated indel mutations as well as to stimulate HDR with both double-stranded plasmid DNA and single-stranded oligonucleotide donor templates. Being able to introduce DSBs at multiple sites in parallel with Cas9 is a unique advantage of this RNA-guided genome editing platform relative to meganucleases, ZFNs or TALENs. For example, expression of Cas9 and multiple gRNAs has been used to induce small and large deletions or inversions between the DSBs 14, [33] [34] [35] , to simultaneously introduce mutations in three genes in rat cells 36 , five genes in mouse ES cells 24 and five genes in the somatic cells of a single zebrafish 37 .
The simplicity of Cas9 targeting has also inspired the generation of large gRNA libraries using array-based oligonucleotide synthesis.
These libraries can be engineered to encompass multiple gRNAs for almost every gene in a host organism, thereby facilitating forward genetic screens and selection. In contrast to short hairpin RNA libraries, which mediate only gene knockdown, these gRNA libraries have been used with Cas9 nuclease to generate libraries of cells with knockout mutations. Libraries consisting of between ~64,000 and ~87,000 distinct gRNAs have demonstrated this strategy for positive and negative forward genetic phenotype screens in human and mouse cells [38] [39] [40] .
Effector domain
Other modification, e.g., chromatin or DNA modification npg r e v i e w Cas9 variants that cut one strand rather than both strands of the target DNA site (known as 'nickases') have also been shown to be useful for genome editing. Introduction of a D10A or H840A mutation into the RuvC1-or HNH-like nuclease domains in Cas9 (Fig. 4a) 41, 42 results in the generation of nickases that cut either the complementary or noncomplementary DNA target strands, respectively, in vitro 7, 12, 43 (Fig. 4b,c) . Consistent with previous studies with ZFN-derived nickases [44] [45] [46] (J.K.J. and colleagues 44 ), Cas9 nickases can, at some sites, induce HDR with reduced levels of concomitant NHEJ-mediated indels 13, 14 . However, although at some sites Cas9 nickases can induce HDR with efficiencies similar to those of the original Cas9 nuclease 13, 14 , these rates can be much lower at other sites 47 . Notably, the frequencies of indel mutations introduced by nickases have also been high at certain sites 13,47-49 (J.K.J. and colleagues 48 ) . Although the precise DNA repair pathways by which these various alterations are induced remain undefined, one potential mechanism that has been postulated is that passage of a replication fork through a nuclease-induced nick site might result in a DNA DSB. Additional studies with Cas9 nickases are needed to better understand locusdependent differences in the relative efficiencies of HDR and indel mutation induced by these enzymes.
Determining the specificities of RNA-guided Cas9 nucleases Although RGNs generally cleave their intended target sites reliably, an important question is, to what extent do these nucleases induce offtarget cleavage events (and therefore unwanted NHEJ-induced indel mutations)? To assess RGN specificity, several groups have created gRNA variants containing one to four nucleotide mismatches in the complementarity region and have then examined the abilities of these molecules to direct Cas9 nuclease activity in human cells at reporter gene (J.K.J. and colleagues 50 ) or endogenous gene 14,51 target sites.
These studies showed that mismatches are generally better tolerated at the 5′ end of the 20-nt targeting region of the gRNA than at the 3′ end; this result is consistent with previous experiments performed in vitro and in bacterial cells, which suggested that the 8-12 bp at the 3′ end of the targeting sequence (also known as the 'seed' sequence) are crucial for target recognition 7, 8, 14, 52, 53 . However, the effects of single and double mismatches are not always predictable based on their location within the gRNA targeting region; some mismatches in the 5′ end can have dramatic effects, whereas some in the 3′ end do not greatly affect Cas9 activity 50 . In addition, not all nucleotide substitutions at a given position necessarily have equivalent effects on activity 51 .
A reciprocal, and perhaps more relevant, approach for studying specificity is to assess the activities of Cas9 at potential off-target genomic DNA target sites, (i.e., sites that have a few nucleotide differences compared to the intended target). A number of studies have examined potential off-target sites that differ at one to six positions from the on-target site in human cells 9, 47, 48, 50, 51, 54 . Collectively, these reports have found cases of off-target mutations at sites that differ by as many as five positions within the protospacer region 50 and/or that have an alternative PAM sequence of the form NAG 51 . Interestingly, indel mutation frequencies at these off-target sites can be high enough (>2-5%) to detect using the relatively insensitive T7 endonuclease I (T7E1) mutation mismatch assay and sometimes are comparable to the on-target site mutation frequency 48, 50, 54 . In addition, more sensitive deep sequencing assays have identified lower frequency off-target mutations 48, 51, 55 . It is important to note that all of these directed studies examined only a subset of the much larger number of potential offtarget sites in the genome. For example, any given 20-nt protospacer will typically have hundreds to thousands of potential off-target sites that differ at four or five positions, respectively, in 6 × 10 9 bases of random DNA. In addition, although it has been suggested that higher GC content at the RNA:DNA hybridization interface might potentially help to stabilize binding of the RGN to DNA, high rates of mutagenesis have been observed for off-target sites with as little as 30% matched GC content 9, 50 .
A somewhat more comprehensive strategy for examining Cas9 specificities is to identify off-target sites from a partially degenerate library of variants that is based on the intended on-target sequence. One recent report identified sites from such libraries based on their abilities to be bound by a catalytically inactive form of Cas9 fused to a transcriptional activation domain (see Fig. 4 and further discussion below) 49 . This study found sites that were mismatched by as many as three (and possibly more) positions relative to the on-target site 49 . These results are similar to those of another study, which used in vitro selection for Cas9 nuclease cleavage activity to identify potential offtarget sites from a partially degenerate library of target site variants. Some of the off-target sites identified by these in vitro selections (with up to four mismatches) were also shown to be mutated in human cells 9 .
A recent study using whole-exome sequencing did not find evidence of Cas9-induced, off-target mutations in three modified human K562 cell line clones 56 . Although the authors acknowledge that the high false-negative rate associated with exome sequencing analysis limits interpretation of these data, these results do suggest that with careful target selection, it may be possible to isolate Cas9-edited cells with otherwise intact exomes. Additional examples with deeper sequencing coverage and whole genome (rather than whole exome) sequencing will be needed to determine how readily cells that do not have off-target mutations can be isolated. The ability to do so would encourage broader research application of Cas9 technology. However, it is worth noting that deep sequencing the genomes of individual cell npg r e v i e w clones is expected to be neither sensitive nor effective for defining the full genome-wide spectrum of Cas9 off-target sites because each clone would likely only carry mutations at a small proportion of, if any, possible off-target sites. Overall, the various published studies strongly suggest that offtarget sites of RNA-guided Cas9 nucleases can be variable in frequency and challenging to predict. For any given target site, it is not currently possible to predict how many mismatches can be tolerated, nor do we fully understand why some sites are cleaved whereas other are not. We also do not know how genomic and/or epigenomic context might affect the frequency of cleavage. Although some initial evidence suggests that DNA methylation does not inhibit Cas9-based genome editing 51 , it seems plausible and likely that chromatin structure could play a role in off-target site accessibility. A more comprehensive understanding of Cas9 off-target effects will have to await the development of unbiased, global measures of Cas9 specificity in cells.
Methods for reducing off-target effects of Cas9 nucleases
Even with an incomplete understanding of RNA-guided Cas9 nuclease specificity, researchers have begun to explore various approaches to reduce off-target mutagenic effects. One potential strategy is to test the effects of reducing the concentrations of gRNA and Cas9 expressed in human cells. Results with this approach have been mixed; one group observed proportionately larger decreases in rates of offtarget relative to on-target mutagenesis for two gRNAs 51 , whereas our group observed nearly proportionate decreases at both off-target and on-target sites for two other gRNAs 50 . The use of modified gRNA architectures with truncated 3′ ends (within the tracrRNA-derived sequence) or with two extra guanine nucleotides appended to the 5′ end (just before the complementarity region) also yielded better on-target to off-target ratios but generally with considerably lower absolute efficiencies of on-target genome editing 9, 56 .
Another proposed approach for improving specificity involves the use of 'paired nickases' in which adjacent off-set nicks are generated at the target site using two gRNAs and Cas9 nickases 47, 49, 56 (Fig. 4d) , a strategy analogous to one originally performed with pairs of engineered zinc finger nickases 46 . In contrast to single Cas9 nickases (which can at some sites more favorably induce HDR events relative to NHEJ indels), paired Cas9 nickases targeted to sites on opposite DNA strands separated by 4 to 100 bp can efficiently introduce both indel mutations and HDR events with a single-stranded DNA oligonucleotide donor template in mammalian cells 47, 49, 56 . It has been proposed by some that the concerted action of paired nickases create a DSB that is then repaired by NHEJ or HDR 47, 55 . Importantly, paired nickases can reduce Cas9-induced off-target effects of gRNAs in human cells; the addition of a second gRNA and substitution of Cas9 nickase for Cas9 nuclease can lead to lower levels of unwanted mutations at previously known off-target sites of the original gRNA 47 . However, an as-yet unanswered question is whether the second gRNA can itself induce its own range of Cas9 nickase-mediated off-target mutations in the genome. Multiple studies have shown that single monomeric Cas9 nickases can function on their own to induce indel mutations at certain genomic loci 13, [47] [48] [49] , perhaps because an individual nick might be converted to a DSB when a replication fork passes through the locus 57, 58 . Thus, an important improvement needed for the paired nickase system will be to make the activities of the two nickase monomers strictly co-dependent on each other for genome editing activity-that is, so that these nickase monomers are only active for genome editing when bound to DNA in close proximity to the other.
Our group has recently shown that off-target effects can be substantially reduced simply by using gRNAs that have been shortened npg r e v i e w at the 5′ end of their complementarity regions 48 . These truncated gRNAs (which we refer to as 'tru-gRNAs') have 17 or 18 nucleotides of complementarity; they generally function as efficiently as full-length gRNAs in directing on-target Cas9 activity but show decreased mutagenic effects at off-target sites and enhanced sensitivity to single or double mismatches at the gRNA:DNA interface 48 . This strategy avoids the technical challenges associated with expressing multiple gRNAs in a single cell for the paired nickase approach and should be straightforward to implement. tru-gRNAs could also be used in conjunction with other strategies for improving Cas9 specificity (e.g., we showed that tru-gRNAs further improve the specificity of paired nickases 48 ) as well as the specificities of dCas9 fusion proteins for non-nuclease applications (described below).
Practical considerations for implementing CRISPR-Cas technology
Owing to rapid progress in the field, potential users face a variety of choices about how to implement CRISPR-Cas technology. Here we discuss some of the parameters to consider when applying the methodology.
Choice of gRNA platform. It is important to note that the efficiency of Cas9 activity for any given locus can be influenced by the architecture of gRNA(s) used. As described above, most recent studies have used a single gRNA that is a fusion of a programmable crRNA and part of the tracrRNA, but earlier studies also used a 'dual gRNA' configuration in which the crRNA and tracrRNA are expressed separately. In general, studies using single gRNAs have consistently reported substantially higher editing rates than those using dual gRNAs 13, 14, 17, 59 . These findings suggest that the single gRNA system may be more active than the double gRNA system, presumably because two components can assemble more efficiently than three components.
In addition, single gRNAs harboring variable lengths of tracrRNA sequence at their 3′ ends have been used by different groups (Supplementary Table 1) . Systematic comparisons have generally demonstrated that longer single gRNAs (containing more of the 3′ portion of the tracrRNA sequence) yield higher editing rates than shorter ones 51 . The most commonly used single gRNA design to date is ~100 nt in length (Supplementary Table 1) . The tru-gRNAs described above are shortened versions of this ~100-nt single gRNA.
Targeting range and choice of gRNA target sites. The choice of promoter used to express gRNAs can limit the options for potential target DNA sites. For example, the RNA polymerase III-dependent U6 promoter or the T7 promoter require a G or GG, respectively, at the 5′ end of the sequence of the RNA that is to be transcribed (top panels of Fig. 5a,b) . As a result, standard full-length or tru-gRNAs expressed from these promoters are limited to targeting sites that match the forms GN [16] [17] [18] [19] NGG or GGN [15] [16] [17] [18] NGG; such sites are expected to occur every 1 in 32 bp or 1 in 128 bp, respectively, in random DNA sequence. Paired nickase strategies require the identification of two sites on opposite strands of DNA with appropriate spacing in between (as described above). One option to reduce these targeting range restrictions is to choose sites without regard to the identities of the first or first two bases at the 5′ end (that is, making gRNAs that are mismatched at these positions). Another potential strategy to bypass these restrictions is to append the required G or GG to the 5′ end of the gRNA, thereby encoding gRNA transcripts that are 1 or 2 bp longer (bottom panels of Fig. 5a,b) . Both of these strategies have been used successfully to produce active gRNAs but with variable efficiencies in genome-editing activities with Cas9 nucleases 47, 54, 56, 60 . Larger-scale studies are needed to clarify the effects of using either mismatched or extended gRNAs on the efficiencies and specificities of RGN-mediated cleavage. Several groups have provided web-based software that facilitates the identification of potential CRISPR RGN target sites in user-defined sequences (e.g., the ZiFiT Targeter software 17, 48 (http://zifit.partners.org/) and the CRISPR Design Tool 51 (http://crispr.mit.edu/)).
Delivery of CRISPR-Cas components. RGNs have been delivered to a broad range of cell types and organisms using a variety of delivery methods. In cultured mammalian cells, researchers have used electroporation 59 , nucleofection 13, 50 and Lipofectamine-mediated transfection 13, 14, 50 of nonreplicating plasmid DNA to transiently express Cas9 and gRNAs. Lentiviral vectors have also been used to constitutively express Cas9 and/or gRNAs in cultured human 38, 39 and mouse 40 cells. RNAs and/or plasmid DNA transcribed in vitro have been injected directly into the embryos of zebrafish 17 , fruit flies 29, 30, 61 , mice 24, 26 and rats 26 . Plasmid DNA and RNA have also been injected into the gonads of adult roundworms 32, [62] [63] [64] [65] [66] , and in one study purified Cas9 protein complexed with gRNA was injected into roundworm gonads 67 . In addition to animal models and cell lines, Cas9 has been used successfully in multiple plant species including wheat, rice, sorghum, tobacco and thale cress using a range of standard delivery methods including PEGmediated transformation of protoplasts, Agrobacterium-mediated transfer in embryos and leaf tissue, and/or bombardment of callus cells with plasmid DNA [19] [20] [21] 23 . For most RGN applications, transient expression of gRNAs and Cas9 is typically sufficient to induce (a) Ranges of potential target sites for gRNAs expressed from a U6 promoter. Target DNA sequence restrictions are imposed by the requirement for a G at the first 5′ nucleotide of the gRNA (blue letters) targeted to the DNA site (required for efficient expression from a U6 promoter) and by the need for an NGG (the PAM sequence; red letters) adjacent to the complementarity region of target site (green letters) (top panel). One strategy to avoid the requirement for a 5′ G in the target site is to append an extra G to the 5′ end of the gRNA (bottom panel). (b) Ranges of potential target sites for gRNAs expressed from a T7 promoter. Target DNA sequence restrictions are imposed by the requirement for a GG at the first two nucleotides of the gRNA targeted to the DNA site (required for efficient expression from the T7 promoter) and by the need for an NGG adjacent to the complementarity region target site (top panel). One strategy to avoid the requirement for a GG dinucleotide in the target sequence is to append an extra GG dinucleotide to the 5′ end of the gRNA (bottom panel).
npg r e v i e w efficient genome editing. Although constitutive expression of RGN components might potentially lead to higher on-target editing efficiencies, extended persistence of these components in the cell might also lead to increased frequencies of off-target mutations, a phenomenon that has been previously reported with ZFNs 68 .
Experimental strategies to control for RGN off-target effects. The existence of CRISPR RGN-induced off-target effects and our current inability to comprehensively identify these alterations on a genomewide scale mean that investigators need to account for the potentially confounding effects of these undesired mutations. Several strategies can be used to rule out off-target mutations as a potential alternative explanation for any phenotypes observed. For example, complementation with reintroduction of a wild-type gene can be used to confirm the effects of knockout mutations. In addition, similar to the strategy of targeting a gene with multiple RNA interference hairpins, one could easily create mutations in the same gene using gRNAs targeted to different sites. Presumably, each gRNA will be expected to have a different range of off-target effects and therefore if the same phenotype is observed with each of these different gRNAs it would seem unlikely that undesired mutations are the cause. The ease with which multiple gRNAs can be rapidly designed and constructed makes it simple and feasible to implement this type of strategy with the Cas9 system. The high efficacy of the Cas9 nuclease for inducing mutations makes it an attractive choice for creating mutant cell lines and whole organisms in spite of the need to account for off-target effects.
Applications of CRISPR-Cas beyond genome editing
Beyond enabling facile and efficient targeted genome editing, the CRISPR-Cas system has the potential to be used to regulate endogenous gene expression or to label specific chromosomal loci in living cells or organisms. Catalytically inactive or "dead" Cas9 (dCas9)-a variant bearing both the D10A and H840A mutations that does not cleave DNA-can be recruited by gRNAs to specific target DNA sites 7, 12 (Fig. 4e) . Targeting of dCas9 to promoters was initially shown to repress gene expression in both Escherichia coli and human cells 69, 70 . Interestingly, dCas9 repressed a bacterial promoter efficiently when recruited with gRNAs that interacted with either strand of sequences upstream of the promoter; however, when targeting sites downstream of the transcription start point, only gRNAs that interacted with the nontemplate strand induced dCas9-mediated repression 69 . dCas9 also provides a general platform for recruitment of heterologous effector domains to specific genomic loci (Figs. 2d-f and 4f) . For example, dCas9 fusions to a transcriptional activation domain (VP64 or the p65 subunit of nuclear factor kappa B; NF-κB) or a transcriptional repression domain (the Krüppel-associated box (KRAB) domain) have been shown to regulate the expression of endogenous genes in human [71] [72] [73] 82 and mouse cells 74 . Changes in gene expression induced by these dCas9 fusions in human cells thus far seem to be generally lower than those induced by similar TALE-based transcription factors 49, [75] [76] [77] [78] . However, multiplex recruitment of dCas9-based activators using between 2 and 10 sgRNAs targeted to the same promoter can result in substantially higher levels of human gene activation, presumably due to the phenomenon of activator synergy 49, 71, 72, 74 (J.K.J. and colleagues 71 ). This capability of dCas9-based activators to function synergistically is consistent with previous observations for TALE-based activators 75, 76 (J.K.J. and colleagues 75 ) in human cells. In future experiments it will be interesting to see whether dCas9 fusions to histone modifiers and proteins involved in altering DNA methylation, such as the ten-eleven translocation (TET) proteins, can also be used to perform targeted 'epigenome editing' (Fig. 2e) , including the alteration of specific histone modifications and demethylation of particular cytosine bases in human cells as has been recently described with TALE DNA-binding domains 73, 79 (J.K.J. and colleagues 80 ).
An alternative strategy for tethering heterologous effector domains to DNA-bound gRNA:dCas9 complexes is to exploit well-defined, RNA-protein interaction pairs. This approach uses two engineered components: a gRNA that has one or two RNA binding sites for the phage MS2 coat protein fused to its 3′ end; and a fusion of MS2 coat protein to an effector domain 49 . Addition of the MS2 RNA binding sequences to the gRNA does not abolish its ability to target dCas9 to specific DNA sites. Furthermore, co-expression of the MS2 coat protein fusion with the hybrid gRNA and dCas9 has been used to recruit activation domains to a gene promoter in human cells 49 . Although the activation observed seems to be somewhat less robust than direct fusions to dCas9, this type of configuration might provide additional options and flexibility for recruitment of multiple effector domains to a promoter by, for example, using multiple gRNAs and MS2 coat protein binding sites on each gRNA to recruit many copies of different domains to the same promoter.
It has also been demonstrated that an EGFP-dCas9 fusion can be used to visualize DNA loci harboring repetitive sequences, such as telomeres, with a single gRNA or nonrepetitive loci using 26 to 36 gRNAs tiled across a 5-kb region of DNA 81 (Fig. 2f) . This imaging strategy provides a powerful tool for studying chromosome dynamics and structure and extends the dCas9 system beyond gene expression-based applications.
Thus far, evidence suggests that the effects of the small number of dCas9-activation or repression domain fusions tested to date can be highly specific in mammalian cells, as judged by RNA-seq or expression microarray experiments 74, 82 ; however, this may be because not all binding events lead to changes in gene transcription. It remains to be determined whether dCas9 fusions are truly specific for single sites in their cellular activities or if, like their nuclease counterparts, strategies (such as the use of tru-gRNAs) will be needed to improve specificity.
Future directions
Progress in the development of Cas9-based technologies over the past 18 months has been stunning, but many interesting questions and applications remain to be addressed and explored.
First, methods for expanding the targeting range of RNA-guided Cas9 will be important for inducing precise HDR or NHEJ events as well as for implementing multiplex strategies, including paired nickases. As noted above, the targeting range for Cas9, paired Cas9 nickases and dCas9 fusions is restricted mainly by the need for a PAM sequence matching the form NGG. Alternative PAM sequences of the form NAG or NNGG can be exploited, as has been noted 7, 8, 51 , but more experiments are needed to ascertain how robustly these sequences are recognized and cleaved. Other gRNA:Cas9 platforms with different PAM sequences isolated from Streptococcus thermophilus, Neisseria meningitidis and Treponema denticola have also been characterized 10, 11, 14 and identification of more of these systems from other species 83 could further enhance the targeting range of the platform.
Second, the field urgently needs to develop unbiased strategies to globally assess the off-target effects of Cas9 nucleases or paired nickases in any genome of interest. Such methods will be crucial for evaluating how effectively improvements described to date enhance the specificity of the platform. In addition, although tru-gRNAs and paired nickases can reduce off-target effects, it is likely that further improvements will be needed, especially for therapeutic applications. Ideally, new strategies could be combined with existing approaches. npg r e v i e w Examples of such improvements might involve using protein engineering to modify Cas9 and/or modifying the nucleotides used by the gRNA to mediate recognition of the target DNA site. Alternatively, the construction of inducible forms of Cas9 and/or gRNAs might provide a means to regulate the active concentration of these reagents in the cell and thereby improve the ratio of on-and off-target effects.
Third, methods for efficient delivery and expression of CRISPRCas system components will undoubtedly need to be optimized for each particular cell-type or organism to be modified. For example, some cell types or tissues might be refractory to transfection and/or infection by standard viral vectors. A related challenge will be to develop methods that enable expression of either the gRNAs or the Cas9 nuclease that is specific to a tissue, cell type or developmental stage. Strategies that ensure efficient expression of large numbers of different gRNAs simultaneously from one vector would also allow more extensive use of the multiplex capability of CRISPR-Cas systems. Collectively, these advances will be important for research use and therapeutic applications.
Lastly, strategies for shifting the balance away from NHEJ-mediated indel mutations and toward HDR-driven alterations remain a priority for development. Although high rates of HDR can be achieved with the CRISPR RGNs and single-stranded DNA oligonucleotides, competing mutagenic NHEJ also occurs simultaneously. This limitation is particularly problematic when using HDR to induce point mutation changes (as opposed to insertions) in the protospacer part of the target site; alleles that have been successfully altered in this way can still be efficiently re-cut and then mutagenized by NHEJ, thereby reducing the yield of correctly edited sequences. One of the drawbacks to developing an approach to improve the HDR:NHEJ ratio is that inhibition of NHEJ is likely to be poorly tolerated by most cells, given its central role in normal DNA repair. For therapeutic applications seeking to exploit HDR, reduction or elimination of competing NHEJ will be crucially important.
The simplicity, high efficiency and broad applicability of the RNAguided Cas9 system have positioned this technology to transform biological and biomedical research. The ease with which researchers can now make changes in the sequence or expression of any gene means reverse genetics can be performed in virtually any organism or cell type of interest. In addition, the construction of large libraries of gRNAs for altering or regulating genes of interest will enable facile, comprehensive forward genetic screens. All of these systems can also be multiplexed by expressing multiple gRNAs in a single cell, thereby further extending the complexity of forward and reverse genetic experiments that can be done. Although the off-target effects of Cas9 remain to be defined on a genome-wide scale, much progress has already been made toward improving specificity, and further advances will undoubtedly come rapidly, given the intensity of research efforts in this area. All of these recent advances-and those to come-in developing and optimizing Cas9-based systems for genome and epigenome editing should propel the technology toward therapeutic applications, opening the door to treating a wide variety of human diseases. 
